Evaluation of the effectiveness of the new anti-tuberculosis drug thiozonide in patients with pulmonary tuberculosis with multiand extensive drug resistance of Mycobacterium tuberculosis

Alla Yu. Savchenko; Савченко А. Ю.; Galina V. Ramenskaya; Раменская Г. В.; Vladimir G. Kukes; Кукес В. Г.; Natalya V. Shilova; Шилова Наталья Владимировна

doi:10.18565/pharmateca.2023.14.112-117

Evaluation of the effectiveness of the new anti-tuberculosis drug thiozonide in patients with pulmonary tuberculosis with multiand extensive drug resistance of Mycobacterium tuberculosis

作者: Savchenko A.Y.¹, Ramenskaya G.V.², Kukes V.G.³, Shilova N.V.⁴
隶属关系:
1. Federal State Institution of Science «Scientific Center of Biomedical Technology of the Federal Medical-Biological Agency of Russia», Svetlye Gory Village
2. I.M. Sechenov First Moscow State Medical University (Sechenov University)
3. Clinical Pharmacology Branch Federal State Institution of Science «Scientific Center of Biomedical Technology of the Federal Medical-Biological Agency of Russia»
4. GEN-LAB ltd
期: 卷 30, 编号 14 (2023)
页面: 112-116
栏目: Pulmonology/ENT/ARVI
URL: https://bakhtiniada.ru/2073-4034/article/view/275673
DOI: https://doi.org/10.18565/pharmateca.2023.14.112-117
ID: 275673

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
全文:
作者简介
参考
补充文件
统计

详细

Objective. Evaluation of the effectiveness of the drug tiozonide included in a comprehensive treatment regimen for patients diagnosed with multidrug-resistant (MDR-TB) or extensive drug-resistant (XDR-TB) pulmonary tuberculosis.

Methods. Evaluation of the safety and efficacy of tiozonide in 160 patients diagnosed with MDR-TB or XDR-TB who were treated as inpatients or outpatients in a multicenter clinical trial, against standard antituberculosis chemotherapy in patients diagnosed with multidrug-resistant or extensive drug-resistant pulmonary tuberculosis. As the main criterion for the effectiveness of combination treatment of patients with MDR and XDR tuberculosis using various doses of the drug thiozonide compared with placebo, the dynamics of the quantitative content of Mycobacterium tuberculosis (MBT) in the sputum of patients, determined by bacterioscopic and bacteriological methods, was assessed.

Results. Analysis of the results of bacterioscopic studies showed a significant decrease in bacterial excretion in patients during long-term treatment in the tiozonide treatment groups. It was most pronounced when taking 400 mg and amounted to 93% at the 10th visit (84th day of treatment) compared to the baseline indicator. Analysis of the results of bacteriological studies, as well as sputum bacterioscopy, showed a significant increase in the rate of decline in bacteriological test indicators in patients taking thiozonide. This reduction was most pronounced in the 400 mg group and amounted to 2 points or 95% at the last 10th visit compared to the pre-treatment value of 2.1 points. Treatment in this group resulted in the absence of MBT in the sputum of most patients.

Conclusion. The results of the evaluation of the effectiveness of the drug thiozonide in the complex therapy of patients with MDRand XDR-TB demonstrated that the use of thiozonide in doses of 400 and 600 mg ensured the achievement of a complex primary endpoint compared with placebo in relation to the dynamics of MBT content in sputum according to the bacterioscopic and bacteriological methods. The data obtained allow to justify the sample size and treatment regimen for the third phase study of the drug thiozonide.

关键词

thiozonide, tuberculosis, multi-drug resistance of Mycobacterium tuberculosis, extensive drug resistance of Mycobacterium tuberculosis, sputum microscopy, microbiological assessment of sputum

全文:

##article.viewOnOriginalSite##

Cand. Sci. (Med.), Director of GEN-LAB ltd

俄罗斯联邦, Moscow

参考

Туберкулез у взрослых. Клинические рекомендации. Министерство здравоохранения Российской Федерации. 2022. [Tuberculosis in adults. Clinical recommendations. Ministry of Health of the Russian Federation. 2022. (In Russ.)].
Uplekar M., Weil D., Lonnroth K., et al. WHO’s new end TB strategy. Lancet. 2015;385: 1799–801.
Peloquin C.A., Davies G.R. The treatment of tuberculosis. Clin. Pharmacol. Ther. 2021;110(6):1455–66. doi: 10.1002/cpt.2261.
Karmakar M., Rodrigues C.H.M., Holt K.E., et al. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. PLoS One. 2019;14(5):e0217169. doi: 10.1371/journal.pone.0217169.
Меньшикова Л.А. Фармакокинетическое исследование оригинального лекарственного средства тиозонида. Дисс. кандидат фарм. наук: М., 2016. [Men’shikova L.A. Pharmacokinetic study of the original drug thiosonide. Diss. Cand. of Med. Sciences Moscow, 2016. (In Russ.)].
Бочарова И.В., Буренков М.С., Лепеха Л.Н. и др. Доклинические исследования специфической активности нового противотуберкулезного препарата тиозонид. Туберкулез и болезни легких. 2014;(6):46–50. [Bocharova I.V., Burenkov M.S., Lepekha L.N., et al. Preclinical studies of the specific activity of the new anti-TB drug thi-osonide. Tuber Lung Dis. 2014;(6):46–50. (In Russ.)]. doi: 10.21292/2075-1230-2014-0-6-46-50
Harris M., Taylor G. Medical statistics made easy. London: Taylor and Francis. 2006.
Шилов Б.В., Савченко А.Ю. Изучение мишеней нового противотуберкулезного препарата группы диарилхинолинов тиозонида. Проблемы биологии и медицины. 2022;141(6.1.):112–16. [Shilov B.V., Savchenko A.Yu. Study of the targets of a new anti-tuberculosis drug of the diarylquinoline group, thiozonide. Problemy biologii i meditsiny. 2022;141(6.1.):112–16. (In Russ.)].
Alajlani M.M. The Chemical Property Position of Bedaquiline Construed by a Chemical Global Positioning System-Natural Product. Molecules. 2022;27(3):753. doi: 10.3390/molecules27030753.
Deshkar A.T., Shirure P.A. Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis. Cureus. 2022;14(8):e28519. doi: 10.7759/cureus.28519.
Belosludtsev K.N., Belosludtseva N.V., Talanov E.Y., et al. Effect of bedaquiline on the functions of rat liver mitochondria. Biochim. Biophys. Acta Biomembr. 2019;1861(1):288–97. doi: 10.1016/j.bbamem.2018.06.012.
Усов К.И., Юшков Г.Г. Фармакологические эффекты комбинированного противотуберкулезного препарата «Протуб-3®» при однократном введении в условиях эксперимента. Acta Biomedi. Scientif. 2013;5(93):158–61. [Usov K.I., Yushkov G.G. Pharmacological effects of the combined anti-tuberculosis drug «Protub-3®» with a single administration under experimental conditions. Acta Biomedi. Scientif. 2013;5(93):158–61. (In Russ.)].
Суханов Д.С., Тимофеев Е.В., Алексеева Ю.С., Азовцев Д.Ю. Лекарственные поражения печени при туберкулезе. Механизмы развития и методы диагностики. Juvenis scientia. 2023;9(1):24–42. [Sukhanov D.S., Timofeev E.V., Alekseeva Yu.S., Azovtsev D.Yu. Drug-induced liver damage in tuberculosis. Mechanisms of development and diagnostic methods. Juvenis scientia. 2023;9(1):24–42. (In Russ.)]. doi: 10.32415/jscientia_2023_9_1_24-42.